Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) agreed with Calvert Labs, an Altasciences company, to design and execute exploratory studies related to Tryp’s psilocybin-for-neuropsychiatric disorders (PFN) program.
The studies will focus on generating toxicology and blood exposure level data for Tryp’s proprietary, psilocybin-based formulation, TRP-8803, while strengthening Tryp’s intellectual property portfolio for the drug product.
Under the accord, Calvert Labs will perform preclinical bridging studies required for TRP-8803 prior to initiating clinical studies with the drug product. Tryp will subsequently work with Altasciences to perform clinical pharmacology studies in healthy, volunteer patients with TRP-8803. These studies will enable the use of TRP-8803 in Tryp’s planned Phase 2b clinical trials for chronic pain and eating disorder indications.
Tryp also entered into an agreement with Gad Consulting Services to advise on certain aspects of the studies performed by Calvert Labs.
“This partnership marks an important milestone for us as we continue to build momentum towards our Phase 2b clinical studies with our proprietary TRP-8803 formulation,” Jim Gilligan, Ph.D., president and CSO of Tryp, said in a statement.
Dr. Gilligan said Calvert Labs and Gad Consulting Services are ideally suited to perform these important studies, given their international expertise in toxicology. “Our work with these organizations and with Altasciences will accelerate our time into the clinic with TRP-8803.”
